title: Does rocuronium-sugammadex reduce myalgia and headache after electroconvulsive therapy in patients with major depression?
abstract: BACKGROUND
  We aimed to compare the effects of succinylcholine and rocuronium-sugammadex on development of myalgia and headache after electroconvulsive therapy (ECT).
  
  
  METHODS
  Forty-five patients undergoing ECT were enrolled in the study. Anesthesia induction was provided with propofol 1 mg/kg intravenously (IV) + succinylcholine 1 mg/kg IV in group S (n = 24) and propofol 1 mg/kg IV + rocuronium 0.3 mg/kg IV in group R (n = 21). Sugammadex 4 mg/kg IV was administered to group R after the motor seizure. The first 3 ECT sessions were evaluated on the basis of time to onset of spontaneous respiration following the induction, time to eye-opening response to verbal stimuli, and visual analog scale (VAS) scores for myalgia and headache at hours 2, 6, 12, and 24 following the ECT for all patients.
  
  
  RESULTS
  The times to onset of spontaneous respiration and eye-opening response to verbal stimuli were significantly shorter in all the 3 sessions in group R compared with group S (P < 0.002). Myalgia VAS scores at hours 2, 6, and 12 and the headache VAS scores at hours 2 and 6 were significantly higher in group S versus group R (P < 0,015).
  
  
  CONCLUSIONS
  We concluded that the rates of myalgia and headache after ECT were significantly lower in group R than in group S, and also the awakening time (spontaneous respiration and opening the eyes in response to verbal stimuli) was significantly shorter in group R compared with group S.
authors.affiliation: From the *Department of Anesthesiology and Reanimation, †Department of Psychiatry, Faculty of Medicine, University of Gaziantep, and ‡Department of Anesthesiology, Obstetrics & Gynecology Hospital, Gaziantep, Turkey.
authors.forename: Vahap
authors.initials: V
authors.lastname: Saricicek
authors.forename: Levent
authors.initials: L
authors.lastname: Sahin
authors.forename: Feridun
authors.initials: F
authors.lastname: Bulbul
authors.forename: Sevgi
authors.initials: S
authors.lastname: Ucar
authors.forename: Mehrican
authors.initials: M
authors.lastname: Sahin
mesh_terms: D000328:Adult; D000368:Aged; D000732:Androstanols / Q000627:therapeutic use*; D000758:Anesthesia; D000762:Anesthesia Recovery Period; D003865:Major Depressive Disorder / Q000150:complications* / Q000628:therapy*; D004565:Electroconvulsive Therapy / Q000009:adverse effects*; D005260:Female; D006261:Headache / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008875:Middle Aged; D063806:Myalgia / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents / Q000627:therapeutic use*; D010147:Pain Measurement; D000077123:Rocuronium; D018401:Sample Size; D012640:Seizures / Q000503:physiopathology; D013390:Succinylcholine; D000077122:Sugammadex; D047408:gamma-Cyclodextrins / Q000627:therapeutic use*
chemical_list: D000732:Androstanols; D009467:Neuromuscular Depolarizing Agents; D003473:Neuromuscular Nondepolarizing Agents; D047408:gamma-Cyclodextrins; D000077122:Sugammadex; D013390:Succinylcholine; D000077123:Rocuronium